Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (1,244) Arrow Down
Filter Results: (1,244) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,244)
    • People  (5)
    • News  (171)
    • Research  (928)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (756)

Show Results For

  • All HBS Web  (1,244)
    • People  (5)
    • News  (171)
    • Research  (928)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (756)
← Page 50 of 1,244 Results →
  • April 1989
  • Supplement

Novel Combination of Two Drugs (C)

By: Regina E. Herzlinger
Keywords: Health; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Find at Harvard
Related
Herzlinger, Regina E. "Novel Combination of Two Drugs (C)." Harvard Business School Supplement 189-170, April 1989.
  • April 1989
  • Supplement

Novel Combination of Two Drugs (B)

By: Regina E. Herzlinger
Keywords: Health; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Find at Harvard
Related
Herzlinger, Regina E. "Novel Combination of Two Drugs (B)." Harvard Business School Supplement 189-169, April 1989.
  • 2006
  • Chapter

BioRisk: interleukin-2 from laboratory to market in the United States and Germany

By: Arthur A. Daemmrich
Keywords: Product Development; Risk and Uncertainty; Health Testing and Trials; Pharmaceutical Industry; Pharmaceutical Industry; United States; Germany
Citation
Related
Daemmrich, Arthur A. "BioRisk: interleukin-2 from laboratory to market in the United States and Germany ." In The Risks of Medical Innovation: Risk Perception and Assessment in Historical Context, edited by Thomas Schlich and Ulrich Tröhler, 242–261. Routledge, 2006.
  • June 2003 (Revised October 2004)
  • Case

Novartis: The Challenge of Success (C)

By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Keywords: Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
  • March 2002 (Revised May 2002)
  • Case

Genzyme: Engineering the Market for Orphan Drugs

Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
  • September 2001
  • Supplement

Millennium Pharmaceuticals, Inc. (B)

By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry; Pharmaceutical Industry; Cambridge
Citation
Purchase
Related
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
  • October 2000
  • Teaching Note

Kendle International Inc. TN

By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
Keywords: Pharmaceutical Industry; Pharmaceutical Industry
Citation
Purchase
Related
Crane, Dwight B., and Indra Reinbergs. "Kendle International Inc. TN." Harvard Business School Teaching Note 201-014, October 2000.
  • January 1999
  • Background Note

Note on the Drugstore Industry

By: David E. Bell and Ann Leamon
In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details
Keywords: History; Industry Growth; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Related
Bell, David E., and Ann Leamon. "Note on the Drugstore Industry." Harvard Business School Background Note 599-079, January 1999.
  • September 1997
  • Case

Bayer AG (B)

By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Germany
Citation
Educators
Purchase
Related
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
  • 2000
  • Chapter

In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals

By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Find at Harvard
Related
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
  • 28 Apr 2009
  • First Look

First Look: April 28, 2009

tilted towards old age than annuities. Several advantages of this are discussed, including some that may explain why tontines have proven popular with consumers in the past. Download the paper: http://www.hbs.edu/research/pdf/09-121.pdf   PublicationsWhere Is the... View Details
Keywords: Martha Lagace
  • Web

Staff Directory | Baker Library

pharmaceutical companies, health care, travel, and personal finance. Avery holds a master’s degree from Columbia Journalism School, a Fulbright Fellowship to Russia, and a bachelor’s degree in history and international relations from... View Details
  • 01 Jun 2000
  • News

The Business of Biotech

business and commercial development at Millennium Pharmaceuticals in Cambridge, Massachusetts. "It will revolutionize how medicine is practiced," he states simply. "Right now the doctor listens to your heart with a stethoscope and maybe... View Details
Keywords: Julia Hanna
  • January 2024
  • Supplement

Accounting Red Flags or Red Herrings at Catalent? (B)

By: Joseph Pacelli, ZeSean Ali and Tom Quinn
GlassHouse Research identified accounting red flags at Catalent. Fiat Lux Partners countered most of GlassHouse’s claims. Who was right? This update explores the aftermath of the short seller duel. View Details
Keywords: Accounting Audits; Acquisition; Budgets and Budgeting; Business Earnings; Earnings Management; Cost Accounting; Fair Value Accounting; Financial Reporting; Revenue Recognition; Integrated Corporate Reporting; Fairness; Moral Sensibility; Values and Beliefs; Government Legislation; Conflict of Interests; Announcements; Blogs; Debates; Lawsuits and Litigation; Stocks; Performance Productivity; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Purchase
Related
Pacelli, Joseph, ZeSean Ali, and Tom Quinn. "Accounting Red Flags or Red Herrings at Catalent? (B)." Harvard Business School Supplement 124-055, January 2024.
  • March 2023
  • Case

Moderna

By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
Keywords: Health Pandemics; Research and Development; Digital Transformation; Health Testing and Trials; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Iansiti, Marco, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen, and Dave Habeeb. "Moderna." Harvard Business School Multimedia/Video Case 623-703, March 2023. (Click here to access this case.)
  • March 2022
  • Teaching Note

Digital Manufacturing at Amgen

By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008. View Details
Keywords: Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information Technology; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Technology Adoption; Pharmaceutical Industry; Pharmaceutical Industry; United States; California; Puerto Rico; Rhode Island
Citation
Purchase
Related
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Teaching Note 622-013, March 2022.
  • February 2021
  • Case

Digital Manufacturing at Amgen

By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is... View Details
Keywords: Digital Technologies; Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Information Technology; Technology Adoption; Pharmaceutical Industry; Pharmaceutical Industry; United States; California; Puerto Rico; Rhode Island
Citation
Educators
Purchase
Related
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
  • November 2020
  • Supplement

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Purchase
Related
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Spreadsheet Supplement 221-705, November 2020.
  • January 2018
  • Teaching Note

BeiGene

By: Willy Shih and Jimmy Zhang
Teaching Note for HBS No. 618-033. View Details
Keywords: Biotechnology; Drug Development; Corporate Strategy; Business Startups; Technological Innovation; Situation or Environment; Pharmaceutical Industry; Pharmaceutical Industry; China
Citation
Purchase
Related
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Teaching Note 618-039, January 2018.
  • June 2014
  • Supplement

Merrimack Pharmaceuticals, Inc. (B)

By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Purchase
Related
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
  • ←
  • 50
  • 51
  • …
  • 62
  • 63
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.